SavedAdd your journal

Journals / Süleyman Demirel Üniversitesi Sağlık Bilimleri Dergisi / 2019 / Cilt: 10 - Sayı: 4

The Potential Drug-Drug Interactions in Alzheimer Patients’ Treatment

MEHTAP SAVRAN
Halil AŞÇI
Nihat ŞENGEZE
Özgür ÖNAL
Serpil DEMİRCİ
Pages
381–388
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

So the pDDI should be kept in mind when a new drug should be added to Alzheimer patient.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Advanced age, as a cause of increased prevalence of co-morbidities, is one of the main risk factors for Alzheimer disease.
📊
Key Findings & Data:Material-Method: Files of patient who applied to a XXX Outpatient Clinic of a tertiary hospital in XXX between 2016-2018 were evaluated retrospectively.
💡
Conclusion & Impact:So the pDDI should be kept in mind when a new drug should be added to Alzheimer patient.
🔬Design:Research Article
📍Scope:2016-2018 Verileri
⚙️Variables:Alzheimers disease · potential drug-drug interaction · elderly

Özet

Objective: Advanced age, as a cause of increased prevalence of co-morbidities, is one of the main risk factors for Alzheimer disease. Co-morbidities accompanying the Alzheimer as well as the disease itself elicit polypharmacy which means two or more drugs used concomitantly. One of the undesirable results of polypharmacy is potential drug-drug interactions (pDDI). The study aimed to evaluate the pDDIs in Alzheimer patients. Material-Method: Files of patient who applied to a XXX Outpatient Clinic of a tertiary hospital in XXX between 2016-2018 were evaluated retrospectively. Rate of polypharmacy, presence and type of pDDI were determinated. Results: In the analyses of 115 files, mean age was 75.13+9.38 and frequency of polypharmacy was calculated as 53.9%. Presence of 3 or more co-morbidites was associated with polypharmacy. pDDI was detected in 77.4% of patients and type C interaction was the most common type. Quetiapine, citalopram/escitalopram, donepezil, risperidone and acetylsalicylic acid were the five drugs that interacted with the maximum number of other medications. Conclusion: The rate of polypharmacy and pDDI as a consequence of polypharmacy could be higher in Alzheimer patients. Some pDDIs could impair the therapeutic effects of Alzheimer drugs in addition to undesirable effects. So the pDDI should be kept in mind when a new drug should be added to Alzheimer patient.

🔖

Cite This Article

SAVRAN, M., AŞÇI, H., ŞENGEZE, N., ÖNAL, Ö., DEMİRCİ, S. (2019). The Potential Drug-Drug Interactions in Alzheimer Patients’ Treatment. Süleyman Demirel Üniversitesi Sağlık Bilimleri Dergisi, Cilt: 10 - Sayı: 4, 381–388. https://ajindex.com/articles/360489

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Akdemir A, Cangöz B, Örsel S, Selekler K. Comparison of patients with mild cognitive impairment and patients with Alzheimer type dementia in terms of implicit memory performance. Turk Psikiyatri Derg 2007;18(2):118-28
  2. Maccioni RB, González A, Andrade V, V., Cortés N, Tapia JP, Guzmán-Martínez L. Alzheimer´ s Disease in the Perspective of Neuroimmunology. The open neurology journal 2018;12:50–6
  3. Winblad B, Amouyel P, Andrieu S, Ballard C, Brayne C, Brodaty H, Fratiglioni L. Defeating Alzheimer’s disease and other dementias: a priority for European science and society. Lancet Neurol 2016;15(5):455–532
  4. Milani RV, Lavie CJ. Health care 2020: reengineering health care delivery to combat chronic disease. The American journal of medicine 2015;128:337-43
  5. Heun R, Schoepf D, Potluri R, Natalwala A. Alzheimer's disease and co-morbidity: increased prevalence and possible risk factors of excess mortality in a naturalistic 7-year follow-up. European Psychiatry 2013;28(1):40-8
  6. Doraiswamy PM, Leon J, Cummings JL, Marin D, Neumann PJ. Prevalence and impact of medical comorbidity in Alzheimer's disease. The Journals of Gerontology Series A: Biological Sciences and Medical Sciences 2002;57:(3)M173-7
  7. Lawler E, Avila A. Alzheimer Disease: Monotherapy vs. Combination Therapy. American family physician 2017;95:452
  8. Masnoon N, Shakib S, Kalisch-Ellett L, Caughey GE. What is polypharmacy? A systematic review of definitions. BMC geriatrics 2017;17(1):230
  9. Yıldırım AB, Kılınç AY. Polypharmacy and drug interactions in elderly patients. Turk Kardiyoloji Dernegi arsivi: Turk Kardiyoloji Derneginin yayin organidir 2017;45: 17-21
  10. Rodvold KA, Kraus DM. Drug interactions involving anti-infective agents. In Antibiotic and Chemotherapy 2010;68–103
  11. Köhler GI, Bode-Böger SM, Busse R, Hoopmann M, Welte T, Böger RH. Drug-drug interactions in medical patients: effects of in-hospital treatment and relation to multiple drug use. International journal of clinical pharmacology and therapeutics 2000;38(11):504-13
  12. Kheshti R, Aalipour M, Namazi S. A comparison of five common drug–drug interaction software programs regarding accuracy and comprehensiveness. Journal of research in pharmacy practice 2016;5(4):257-63. 13. “Lexicomp® Drug Interactions.” [Online]. Available:
  13. Maresova P, Mohelska H, Dolejs J, Kuca K. Socio-economic aspects of Alzheimer's disease. Current Alzheimer Re